Targeting cancer stem cells for treatment of glioblastoma multiforme

Cell Transplantation

Volumn 22, Issue 4, 2013, Pages 731-739

  Cho, Der Yang ^a,b   Lin, Shinn Zong ^a,b,c   Yang, Wen Kuang ^a,b   Lee, Han Chung ^a,b   Hsu, Den Mei ^a   Lin, Hung Lin ^a   Chen, Chun Chung ^a,b   Liu, Chun Lin ^a   Lee, Wen Yuan ^a,b   Ho, Li Hui ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

Bone morphogenetic protein 4 (BMP4); Cancer stem cells (CSCs); Dendritic cells (DCS); Gene therapy; Glioblastoma multiforme (GBM); Immunotherapy; Nonsteroidal anti inflammatory drugs (NSAIDs); Radiosensitizers

Indexed keywords

BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 4; CARMUSTINE; CETUXIMAB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; GEFITINIB; NIMOTUZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; RECEPTOR PROTEIN; VASCULOTROPIN;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG TARGETING; GENE THERAPY; GLIA CELL; GLIOBLASTOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; SURVIVAL RATE;

BRAIN NEOPLASMS; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; NEOPLASTIC STEM CELLS;

EID: 84876487189     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X655136     Document Type: Review

References (74)

1. Aguado, T.; Carracedo, A.; Julien, B.; Velasco, G.; Milman, G.; Mechoulam, R.; Alvarez, L.; Guzmán, M.; Galve-Roperh, I. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J. Biol. Chem. 282(9):6854-6862; 2007.
2. Ahmed, N.; Salsman, V. S.; Kew, Y.; Shaffer, D.; Powell, S.; Zhang, Y. J.; Grossman, R. G.; Heslop, H. E.; Gottschalk, S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2):474-485; 2010.
3. Aloy, M. T.; Hadchity, E.; Bionda, C.; Diaz-Latoud, C.; Claude, L.; Rousson, R.; Arrigo, A. P.; Rodriguez-Lafrasse, C. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 70(2):543-553; 2008.
4. Altaner, C. Glioblastoma and stem cells. Neoplasma 55(5):369-374; 2008.
5. Balyasnikova, I. V.; Franco-Gou, R.; Mathis, J. M.; Lesniak, M. S. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J. Tissue Eng. Regen. Med. 4(4):247-258; 2010.
6. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cell promotes radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756-760; 2006.
7. Bar, E. E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A. L.; DiMeco, F.; Olivi, A.; Eberhart, C. G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25(10):2524-2533; 2007.
8. Beier, D.; Rohri, S.; Pillai, D. R.; Schwarz, S.; Kunz- Schughart, L. A.; Leukei, P.; Prescholdt, M.; Brawanski, A.; Bogahn, U.; Trampe-Kieslich, A.; Giebel, B.; Wischhusen, J.; Reifenberger, G.; Hau, P.; Beier, C. P. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 68(14):5706-5715; 2008.
9. Borovski, T.; Verhoeff, J. J.; ten Cate, R.; Cameron, K.; de Vries, N. A.; van Tellingen, O.; Richel, D. J.; van Furth, W. R.; Medema, J. P.; Sprick, M. R. Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int. J. Cancer 125(5):1222-1230; 2009.
10. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T. L.; Fuller, C.; Hamner, B.; Oh, E. Y.; Gaber, M. W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I. T.; Zakharenko, S. S.; Gajjar, A.; Davidoff, A.; Gilbertson, R. J. A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69-82; 2007.
11. Casper, D.; Lekhuaj, R.; Yaparpalvi, U. S.; Pidel, A.; Jaggernauth, W. A.; Werner, P.; Tribius, S.; Rowe, J. D.; LaSala, P. A. Acetaminophen selectively reduces glioma cell growth and increases radiosensitivity in culture. J. Neurooncol. 46(3):215-229; 2000.
12. Chalmers, A. J. Radioresistant glioma stem cells- therapeutic obstacle or promising target? DNA Repair 6(9):1391-1394; 2007.
13. Chang, C. J.; Hsu, C. C.; Yung, M. C.; Chen, K. Y.; Tzao, C.; Wu, W. F.; Chou, H. Y.; Lee, Y. Y.; Lu, K. H.; Chiou, S. H.; Ma, H. I. Enhanced radiosensitivity and radiationinduced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem. Biophys. Res. Commun. 380(2):236-342; 2009.
14. Chang, T. A.; Morin, P. T.; Vogelstein, B.; Kinzler, K. W. Mechanisms underlying nonsteroidal antiflammatory drugmediated apoptosis. Proc. Natl. Acad. Sci. USA 95(2):681-686; 1998.
15. Cho, D. Y.; Lin, S. Z.; Yang, W. K.; Hsu, D. M.; Lee, H. C.; Lee, W. Y.; Liu, S. P. Recent advances of dendritic cells (DCs)-base immunotherapy for malignant gliomas. Cell Transplant. 18(9):977-983; 2009.
16. +) in malignant gliomas. Cell Transplant. 20(1):121-125; 2011.
17. Davis, F. G.; Frees, S.; Grutsch, J.; Barlas, S.; Brem, S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis base on surveillance, epidemiology, end results (SEER) data 1973-1991. J. Neurosurg. 88(1):1-10; 1998.
18. Dey, M.; Ulasov, I. V.; Lesniak, M. S. Virotherapy against malignant glioma stem cells. Cancer Lett. 289(1):1-10; 2010.
19. Di Cristofano, A.; Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell 100(4):387-390; 2000.
20. Diaz Miqueli, A.; Rolff, J.; Lemm, M.; Fichtner, I.; Perez, R.; Montero, E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br. J. Cancer 100(6):950-958; 2009.
21. Duhem-Tonnelle, V.; Bièche, I.; Vacher, S.; Loyens, A.; Maurage, C. A.; Collier, F.; Baroncini, M.; Blond, S.; Prevot, V.; Sharif, A. Differential distribution of erbB receptors in human glioblastoma multiforme: Expression of erbB3 in CD133-positive putative cancer stem cells. J. Neuropathol. Exp. Neurol. 69(6):606-622; 2010.
22. Fan, X.; Khaki, L.; Zhu, T. S.; Soules, M. E.; Talsma, C. E.; Gul, N.; Koh, C.; Zhang, J.; Li, Y. M.; Maciaczyk, J.; Nikkhah, G.; Dimeco, F.; Piccirillo, S.; Vescovi, A. L.; Eberhart, C. G. NOTCH pathway blockade depletes CD133- positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28(1):5-16; 2010.
23. Fan, X.; Salford, L. G.; Widegren, B. Glioma stem cell: Evidence and limitation. Semin. Cancer Biol. 17(3):214-218; 2007.
24. Fu, J.; Liu, Z. G.; Liu, X. M.; Chen, F. R.; Shi, H. L.; Pangjesse, C. S.; Ng, H. K.; Chen, Z. P. Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin. Med. J. 122(11):1255-1259; 2009.
25. Gadji, M.; Crous, A. M.; Fortin, D.; Krcek, J.; Torchia, M.; Mai, S.; Drouin, R.; Klonisch, T. EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts. Eur. J. Pharmacol. 625(1-3):23-30; 2009.
26. Gal, H.; Pandi, G.; Kanner, A. A.; Ram, Z.; Lithwick-Yanai, G.; Amariglio, N.; Rechavi, G.; Givol, D. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem. Biophys. Res. Commun. 376(1):86-90; 2008.
27. Gangemi, R. M.; Griffero, F.; Marubbi, D.; Perera, M.; Capra, M. C.; Malatesta, P.; Ravetti, G. L.; Zona, G. L.; Daga, A. Corte G. SOX2 silencing in glioblastoma tumorinitiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27(1):40-48; 2009.
28. Ghebeh, H.; Bakr, M. M.; Dermime, S. Cancer stem cell immunotherapy: The right bullet for the right target. Hematol. Oncol. Stem Cell Ther. 1(1):1-2; 2008.
29. Gilbertson, R. J.; Rich, J. N. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7(10):733-736; 2007.
30. Guessous, F.; Zhang, Y.; diPierro, C.; Marcinkiewicz, L.; Sarkaria, J.; Schiff, D.; Buchanan, S.; Abounader R. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med. Chem. 10(1):28-35; 2010.
31. Halatsch, M. E.; Schmidt, U.; Bötefür, I. C.; Holland, J. F.; Ohnuma, T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J. Neurosurg. 92(2):297-305; 2000.
32. Hermann, P. C.; Bhaskar, S.; Cioffi, M.; Heeschen, C. Cancer stem cells in solid tumors. Semin. Cancer Biol. 20(2):77-84; 2010.
33. + cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int. J. Hematol. 77(2):175-179; 2003.
34. Hovinga, K. E.; Shimizu, F.; Wang, R.; Panagiotakos, G.; Van Der Heijden, M.; Moayedpardazi, H.; Correia, A. S.; Soulet, D.; Major, T.; Menon, J.; Tabar, V. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28(6):1019-1029; 2010.
35. Hughes, S. A.; Achanta, P.; Ho, A. L.; Duenas, V. J.; Quiñones-Hinojosa, A. Biological horizons for targeting brain malignancy. In: Jandial R., ed. Frontiers in Brain Repair. New York, NY: Landes Bioscience and Springer Science + Business Media; 2010:93-104.
36. Ji, J.; Black, K. L.; Yu, J. S. Glioma stem cell research for the development of immunotherapy. Neurosurg. Clin. N. Am. 21(1):159-166; 2010.
37. Johannessen, T. C.; Bjerkvig, R.; Tysnes, B. B. DNA repair and cancer stem-like cells-potential partners in glioma drug resistance? Cancer Treat. Rev. 34(6):558-567; 2008.
38. Kang, M. K.; Kang, S. K. Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. Biochem. Biophys. Res. Commun. 373(4):539-544; 2008.
39. Kelly, K. A.; Kirkwood, J. M.; Kapp, D. S. Glioblastoma multiforme: Pathology, natural history and treatment. Cancer Treat. Rev. 11(1):1-26; 1984.
40. Krichevsky, A. M.; Gabriely, G. miR-21: A small multifaceted RNA. J. Cell. Mol. Med. 13(1):39-53; 2009.
41. Lefranc, F. Editorial: On the road to multi-modal and pluridisciplinary treatment of glioblastomas. Acta Neurochir. 151(2):109-112; 2009.
42. Lefranc, F.; Rynkowski, M.; De Witte O.; Kiss, R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv. Tech. Stand. Neurosurg. 34:3-35; 2009.
43. Legler, J. M.; Ries, L. A.; Smith, M. A.; Warren, J. L.; Heineman, E. F.; Kaplan, R. S.; Linet, M. S. Cancer surveillance series (corrected): Brain and other central nervous system cancers: Recent trends in incidence and mortality. J. Natl. Cancer Inst. 91(16):1382-1390; 1999.
44. Li, Y.; Guessous, F.; Zhang, Y.; Dipierro, C.; Kefas, B.; Johnson, E.; Marcinkiewicz, L.; Jiang, J.; Yang, Y.; Schmittgen, T. D.; Lopes, B.; Schiff, D.; Purow, B.; Abounader, R. MicroRNA- 34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69(19):7569-7576; 2009.
45. Liu, G.; Yuan, X.; Zeng Z.; Tunici, P.; Ng, H.; Abdulkadir, I. R.; Lu, L.; Irvin, D.; Black, K. L.; Yu, J. S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5:67-78; 2006.
46. Lubensky, I. A.; Vortmeyer, A. O.; Kim, S.; Lonser, R. R.; Park, D. M.; Ikejiri, B.; Li, J.; Okamoto, H.; Walbridge, S.; Ryschkewitsch, C.; Major, E.; Oldfield, E. H.; Zhuang, Z. Identification of tumor precursor cells in the brains of primates with radiation-induced de novo glioblastoma multiforme. Cell Cycle 5(4):452-456; 2006.
47. Luther, N.; Cheung, N. K.; Souliopoulos, E. P.; Karempelas, I.; Bassiri, D.; Edgar, M. A.; Guo, H. F.; Pastan, I.; Gutin, P. H.; Souweidane, M. M. Interstitial infusion of gliomatargeted recombinant immunotoxin 8H9scFv-PE38. Mol. Cancer Ther. 9(4):1039-1046; 2010.
48. Marian, C. O.; Cho, S. K.; McEllin, B. M.; Maher, E. A.; Hatanpaa, K. J.; Madden, C. J.; Mickey, B. E.; Wright, W. E.; Shay, J. W.; Bachoo, R. M. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 16(1):154-163; 2010.
49. Martin, V.; Liu, D.; Gomez-Manzano, C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr. Pharm. Des. 15(4):353-364; 2009.
50. Michelakis, E. D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T. L.; Mackey, J. R.; Fulton, D.; Abdulkarim, B.; McMurtry, M. S.; Petruk, K. C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2(31):31-34; 2010.
51. Mirimanoff, R. O.; Gorlia, T.; Mason, W.; Van den Bent, M. J.; Kortmann, R. D.; Fisher, B.; Reni, M.; Brandes, A. A.; Curschmann, J.; Villa, S.; Cairncross, G.; Allgeier, A.; Lacombe, D.; Stupp, R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of EORTC 26981/22981-NCIC CE3 phase III randomized trial. J. Clin. Oncol. 24(16):2563-2569; 2006.
52. Molofsky, A. V.; Pardal, R.; Iwashita, T.; Park, I. K.; Clarke, M. F.; Morrison, S. J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425(6961):962-967; 2003.
53. Nakai, E.; Park, K.; Yawata, T.; Chihara, T.; Kumazawa, A.; Nakabayashi, H.; Shimizu, K. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest. 27(9):901-908; 2009.
54. Nicolis, S. K. Cancer stem cells and "stemness" genes in neuro-oncology. Neurobiol. Dis. 25(2):217-229; 2007.
55. Oka, N.; Soeda, A.; Noda, S.; Iwama, T. Brain tumor stem cell from an adenoid glioblastoma multiforme. Neurol. Med. Chir. 49(4):146-151; 2009.
56. Pellegatta, S.; Poliani P. L.; Corno, D.; Menghi, F.; Ghielmetti, F.; Suarez-Merino, B.; Caldera, V.; Nava, S.; Ravanini, M.; Facchetti, F.; Bruzzone, M. G.; Finocchiaro, G. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 66(21):10247-10252; 2006.
57. Pérez Castillo, A.; Aguilar-Morante, D.; Morales-García, J. A.; Dorado, J. Cancer stem cell and brain tumors. Clin. Transl. Oncol. 10(5):262-267; 2008
58. Piccirillo, S. G.; Reynolds, B. A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F.; Vescovi, A. L. Bone morphogenetic proteins inhibit the tumororigenic potentials of human brain tumor-iinitating cells. Nature 444(7120):761-765; 2006.
59. Piccirillo, S. G.; Vescovi, A. L. Brain tumour stem cells: Possibilities of new therapeutic strategies. Expert Opin. Biol. Ther. 7(8):1129-1135; 2007.
60. Rappa, G.; Mercapide, J.; Anzanello, F.; Prasmickaite, L.; Xi, Y.; Ju, J.; Fodstad, O.; Lorico, A. Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp. Cell Res. 314(10):2110-2122; 2008.
61. Sakariassen, P. Ø.; Immervoll, H.; Chekenya, M. Cancer stem cells as mediators of treatment resistance in brain tumors: Status and controversies. Neoplasia 9(11):882- 892; 2007.
62. Sauvageot, C. M.; Weatherbee, J. L.; Kesari, S.; Winters, S. E.; Barnes, J.; Dellagatta, J.; Ramakrishna, N. R.; Stiles, C. D.; Kung, A. L.; Kieran, M. W.; Wen, P. Y. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 11(2):109-121; 2009.
63. Schulenburg, A.; Ulrich-Pur, H.; Thurnher, D.; Erovic, B.; Florian, S.; Sperr, W. R.; Kalhs, P.; Marian, B.; Wrba, F.; Zielinski, C. C.; Valent, P. Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer 107(10):2512-2520; 2006.
64. Sherry, M. M.; Reeves, A.; Wu, J. K.; Cochran, B. H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27(10):2383-2392; 2009.
65. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squrire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D; Dirks, P. B. Identification of human brain tumor initiating cells. Nature 432:396-401; 2004.
66. Stea, B.; Falsey, R.; Kislin, K.; Patel, J.; Glanzberg, H.; Carey, S.; Ambrad, A. A.; Meuillet, E. J.; Martinez, J. D. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett. 202(1):43-51; 2003.
67. Stupp, R.; Dietrich, P. Y.; Kraljevic, S. O.; Pica, A.; Maillard, I.; Maeder, P.; Miuli, R. J.; Pizzolato, G.; Miralbell, R.; Parchet, F.; Regli, L.; Tribolet, N.; Mirimanoff, R. O.; Leyvraz, S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20(5):1375-1382; 2002.
68. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N. Engl. J. Med. 352(10):987-996; 2005.
69. + cells correlates with malignancy of gliomas. Mol. Cell. Neurosci. 43(1):51-59; 2010.
70. Wen, P. Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359(5):492-507; 2008.
71. Xu, Q.; Liu, G.; Yuan, X.; Xu, M.; Wang, H.; Ji, J.; Konda, B.; Black, K. L.; Yu, J. S. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cellassociated antigens. Stem Cells 27(8):1734-1740; 2009.
72. Xu, Y.; Stamenkovic, I.; Yu, Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 70(6):2455-2464; 2010.
73. Yao, Y.; Tao, R.; Wang, X.; Wang, Y.; Mao, Y.; Zhou, L. F. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009 11(6):757-766; 2009.
74. Zhang, P.; Lathia, J. D.; Flavahan, W. A.; Rich, J. N.; Mattson, M. P. Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci. 32(11):559-565; 2009.